Minimal residual disease (MRD) assessment has revolutionized the clinical management of pediatric leukemias but has remained challenging to implement in pediatric brain tumors. In this issue of Cancer Cell, Liu et al. describe an approach to measuring MRD in pediatric medulloblastoma through the use of cell-free DNA in cerebrospinal fluid, with important prognostic implications.

中文翻译：

---

测序发现隐藏的髓母细胞瘤细胞

微小残留病 (MRD) 评估已经彻底改变了小儿白血病的临床管理，但在小儿脑肿瘤中实施仍然具有挑战性。在本期Cancer Cell 中，Liu 等人。描述了一种通过使用脑脊液中的无细胞 DNA 来测量小儿髓母细胞瘤 MRD 的方法，具有重要的预后意义。